NCT03921671 2024-05-29
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
Clinical Trials
9 trialsNCT06169410 2024-01-23
Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
Xijing Hospital
Phase 4 Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT04040361 2022-04-06
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
National Cancer Center Hospital East
Phase 2 Unknown
NCT04632459 2022-03-11
Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Unknown
NCT02970539 2022-02-16
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Athenex, Inc.
Phase 1 Unknown
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT03966118 2019-06-03
AIO-STO-0218
Charite University, Berlin, Germany
Phase 2 Unknown